Scribe Therapeutics set for New York debut after upsized $128.7 million IPO
BUZZ-Scribe Therapeutics set for New York debut after upsized $128.7 million IPO ** Gene-editing startup Scribe Therapeutics SCTX.O set for New York debut later on Friday after upsized $128.7 million U.S. IPO
** Alameda, California-based SCTX sold ~8.6 million shares at $15 apiece
** SCTX, which is building a portfolio of genetic medicines for cardiometabolic diseases, had earlier marketed 7.2 million shares at between $13 and $15 apiece
** Its lead candidate, STX-1150, is being developed to lower low-density lipoprotein cholesterol levels, a key driver of cardiovascular risk
** Every 40 seconds, someone in the U.S. suffers a heart attack, and each year, heart disease costs the nation more than $400 billion, according to the American Heart Association
** Leerink Partners, Goldman Sachs, Guggenheim Securities and Wells Fargo Securities acted as joint book-running managers for offering
(Reporting by Arasu Kannagi Basil in Bengaluru)
Recent news on Scribe Therapeutics
See all newsBrief: Scribe Therapeutics Reports Second Quarter 2026 Financial Results And Recent Corporate Highlights
Scribe Therapeutics surges in New York debut after upsized $128.7 million IPO
U.S. STOCKS ON THE MOVE-Tenet, SLB, Digital Realty
U.S. STOCKS ON THE MOVE-Booz Allen Hamilton, Sensient, Amkor
NASDAQ RESUMED AT 11:50 AM